• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

饮食疗法和运动对缓慢进展性1型糖尿病胰岛素分泌的改善及维持作用:五年随访研究

Improvement and Retention of Insulin Secretion in Slowly Progressive Type 1 Diabetes Mellitus by Diet Therapy and Exercise for Five Years.

作者信息

Sato Toshihiro, Tsujimoto Tetsuro, Kobayashi Michi, Kajio Hiroshi

机构信息

Department of Diabetes, Endocrinology, and Metabolism, National Center for Global Health and Medicine, Japan.

Department Diabetes, Metabolism and Endocrinology, Tohoku University graduate school of medicine, Japan.

出版信息

Intern Med. 2025 Jul 15;64(14):2192-2196. doi: 10.2169/internalmedicine.4648-24. Epub 2024 Dec 26.

DOI:10.2169/internalmedicine.4648-24
PMID:39721688
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12331332/
Abstract

There are no clear strategies for non-insulin-dependent slowly progressive type 1 diabetes mellitus (SPIDDM). We herein report a 25-year-old man with SPIDDM in whom appropriate diet therapy and exercise improved the initial insulin secretion without medication. After 12 months, his body weight decreased by 5.4 kg, and his muscle mass increased from 0.77 to 0.81 kg/body weight. Glycated hemoglobin levels were reduced from 6.4% to 5.7%. HOMA-IR decreased from 1.70 to 0.77; in particular, the insulinogenic index improved from 0.04 to 0.13. These improvements were maintained over five years with continuous lifestyle interventions. Patients with non-insulin-dependent SPIDDM may recover and retain their insulin secretion through lifestyle interventions.

摘要

对于非胰岛素依赖型缓慢进展性1型糖尿病(SPIDDM),目前尚无明确的治疗策略。我们在此报告一名25岁的SPIDDM男性患者,通过适当的饮食治疗和运动,在未使用药物的情况下改善了初始胰岛素分泌。12个月后,他的体重下降了5.4千克,肌肉量从0.77千克/体重增加到0.81千克/体重。糖化血红蛋白水平从6.4%降至5.7%。HOMA-IR从1.70降至0.77;特别是胰岛素生成指数从0.04提高到0.13。通过持续的生活方式干预,这些改善在五年内得以维持。非胰岛素依赖型SPIDDM患者可能通过生活方式干预恢复并保留其胰岛素分泌。

相似文献

1
Improvement and Retention of Insulin Secretion in Slowly Progressive Type 1 Diabetes Mellitus by Diet Therapy and Exercise for Five Years.饮食疗法和运动对缓慢进展性1型糖尿病胰岛素分泌的改善及维持作用:五年随访研究
Intern Med. 2025 Jul 15;64(14):2192-2196. doi: 10.2169/internalmedicine.4648-24. Epub 2024 Dec 26.
2
Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling.用于管理1型糖尿病患者血糖水平的混合闭环系统:系统评价与经济建模
Health Technol Assess. 2024 Dec;28(80):1-190. doi: 10.3310/JYPL3536.
3
Exercise for type 2 diabetes mellitus.2型糖尿病的运动
Cochrane Database Syst Rev. 2006 Jul 19;2006(3):CD002968. doi: 10.1002/14651858.CD002968.pub2.
4
Treatment of periodontal disease for glycaemic control in people with diabetes mellitus.糖尿病患者控制血糖的牙周疾病治疗
Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD004714. doi: 10.1002/14651858.CD004714.pub3.
5
Utility of the random C-peptide and random C-peptide index at diagnosis as a predictor of disease type and long-term insulin secretory capacity in children with diabetes mellitus.随机C肽及随机C肽指数在糖尿病患儿诊断时作为疾病类型及长期胰岛素分泌能力预测指标的效用。
Endocr J. 2025 Jun 2;72(6):697-705. doi: 10.1507/endocrj.EJ24-0517. Epub 2025 Mar 5.
6
Lifestyle interventions for the treatment of women with gestational diabetes.生活方式干预治疗妊娠期糖尿病女性
Cochrane Database Syst Rev. 2017 May 4;5(5):CD011970. doi: 10.1002/14651858.CD011970.pub2.
7
Insulin for the treatment of women with gestational diabetes.用于治疗妊娠期糖尿病女性的胰岛素。
Cochrane Database Syst Rev. 2017 Nov 5;11(11):CD012037. doi: 10.1002/14651858.CD012037.pub2.
8
Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.替尔泊肽10毫克和15毫克与司美格鲁肽2.4毫克治疗2型糖尿病患者肥胖和超重的间接比较疗效与安全性
Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16508.
9
Nonpharmacological interventions on glycated haemoglobin in youth with type 1 diabetes: a Bayesian network meta-analysis.非药物干预对 1 型糖尿病青少年糖化血红蛋白的影响:贝叶斯网络荟萃分析。
Cardiovasc Diabetol. 2024 Jul 1;23(1):230. doi: 10.1186/s12933-024-02301-3.
10
Interventions for preventing weight gain after smoking cessation.戒烟后预防体重增加的干预措施。
Cochrane Database Syst Rev. 2012 Jan 18;1:CD006219. doi: 10.1002/14651858.CD006219.pub3.

本文引用的文献

1
Prediction of future insulin-deficiency in glutamic acid decarboxylase autoantibody enzyme-linked immunosorbent assay-positive patients with slowly-progressive type 1 diabetes.谷氨酸脱羧酶自身抗体酶联免疫吸附试验阳性、缓慢进展的 1 型糖尿病患者未来发生胰岛素缺乏的预测。
J Diabetes Investig. 2024 Jul;15(7):835-842. doi: 10.1111/jdi.14178. Epub 2024 Mar 7.
2
New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): Report from Committee on Type 1 Diabetes of the Japan Diabetes Society (English version).2023 年新诊断标准(缓慢进展型 1 型糖尿病):日本糖尿病学会 1 型糖尿病委员会报告(英文版)。
J Diabetes Investig. 2024 Feb;15(2):254-257. doi: 10.1111/jdi.14121. Epub 2024 Jan 7.
3
Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes.
巴利昔替尼与新发 1 型糖尿病患者的β细胞功能。
N Engl J Med. 2023 Dec 7;389(23):2140-2150. doi: 10.1056/NEJMoa2306691.
4
Combined lifestyle factors and the risk of LADA and type 2 diabetes - Results from a Swedish population-based case-control study.联合生活方式因素与 LADA 和 2 型糖尿病的风险 - 基于瑞典人群的病例对照研究结果。
Diabetes Res Clin Pract. 2021 Apr;174:108760. doi: 10.1016/j.diabres.2021.108760. Epub 2021 Mar 17.
5
Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel.成人隐匿性自身免疫性糖尿病的管理:国际专家小组的共识声明。
Diabetes. 2020 Oct;69(10):2037-2047. doi: 10.2337/dbi20-0017. Epub 2020 Aug 26.
6
Japanese Clinical Practice Guideline for Diabetes 2019.《2019年日本糖尿病临床实践指南》
Diabetol Int. 2020 Jul 24;11(3):165-223. doi: 10.1007/s13340-020-00439-5. eCollection 2020 Jul.
7
Slowly Progressive Type 1 Diabetes Mellitus: Current Knowledge And Future Perspectives.缓慢进展型1型糖尿病:当前认知与未来展望
Diabetes Metab Syndr Obes. 2019 Nov 28;12:2461-2477. doi: 10.2147/DMSO.S191007. eCollection 2019.
8
Adiponectin/AdipoR Research and Its Implications for Lifestyle-Related Diseases.脂联素/脂联素受体研究及其对生活方式相关疾病的影响。
Front Cardiovasc Med. 2019 Aug 14;6:116. doi: 10.3389/fcvm.2019.00116. eCollection 2019.
9
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.抗 CD3 抗体,特利珠单抗,用于 1 型糖尿病风险亲属。
N Engl J Med. 2019 Aug 15;381(7):603-613. doi: 10.1056/NEJMoa1902226. Epub 2019 Jun 9.
10
Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S).二肽基肽酶-4抑制剂西他列汀对非胰岛素依赖期缓慢进展1型糖尿病(SPIDDM)的可能长期疗效:一项开放标签随机对照试验(SPAN-S)
Diabetes Ther. 2017 Oct;8(5):1123-1134. doi: 10.1007/s13300-017-0299-7. Epub 2017 Sep 19.